Skip to main content

Table 2 Tumour response

From: A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027

Parameter

Full analysis set

N = 37

EGFR mutation

Del19

n = 22

L858R

n = 15

Best response, n (%)

 CR

2 (5.4)

2 (9.1)

0

 PR

26 (70.3)

14 (63.6)

12 (80.0)

 SD

5 (13.5)

3 (13.6)

2 (13.3)

 PD

2 (5.4)

1 (4.5)

1 (6.7)

 NE

2 (5.4)

2 (9.1)

0

ORR, n (%)

(95% CI)

28 (75.7)

(58.8–88.2)

16 (72.7)

(49.8–89.3)

12 (80.0)

(51.9–95.7)

DCR, n (%)

(95% CI)

33 (89.2)

(74.6–97.0)

19 (86.4)

(65.1–97.1)

14 (93.3)

(68.1–99.8)

  1. Abbreviations: CI confidence interval, CR complete response, DCR disease control rate, EGFR epidermal growth factor receptor, NE not evaluable, ORR objective response rate, PD progressive disease, PR partial response, SD stable disease
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us